healthy volunteers
Conditions
Interventions
Group 1: Leucine rich aminoacid product (Flexagil CROC): 3.2 g L-Leucine, 0.9 g L-Valine,
0.9 g L-Isoleucine 1x/day (powder) for 12 weeks
Group 2: placebo
Sponsors
Seven Seas Ltd
Eligibility
Sex/Gender
All
Age
55 Years to 75 Years
Inclusion criteria
Inclusion criteria: BMI: 19 - 30 kg/m2 Low to normal protein diet Healthy volunteers with borderline to normal muscle mass
Exclusion criteria
Exclusion criteria: Volunteers with high protein diet (> 1,2 g / kg body weight) or additional intake of protein supplements Relevant history or presence of any medical disorder, potentially interfering with this study Intake of medications that directly affect parameters of muscle or joint function Regular intake of dietary supplements affecting muscle or joint function Known history of heart problems
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of maximal voluntary contraction (MVC) before and after 12 weeks leucine-supplementation in comparison to placebo. MVC was determined via dynamometry | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of the following parameter before and afer 12week Leucine supplementation in comparison to placebo: Measurement joint stability (movement analysis) Body Impedance analysis (BIA) IL-6 Creatin Kinase (CK) collagen collagenase cleavage neoepitope (C2C C-propeptide of type II procollagen (CP2) Quality of life (SF-36) Change of the following parameter before and 0h, 3h, 24h, 48h, 72h after eccentric Load, before and after 12week supplementation of leucine in comparison to placebo: Maximal voluntary contraction (MVC) Muscle soreness (VAS) collagen collagenase cleavage neoepitope (C2C C-propeptide of type II procollagen (CP2) adverse events | — |
Countries
Germany
Contacts
Public ContactClaudia Reule
BioTeSys GmbH
Outcome results
None listed